Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed diffuse large B-cell lymphoma, meeting criteria for 1 of the following:
• * Relapsed after prior high-dose chemotherapy with stem cell support
• * Relapsed after prior chemotherapy, including at least 1 prior standard non-Hodgkin's chemotherapy regimen, but not a candidate for high-dose chemotherapy with stem cell support
• Measurable disease
• * At least 1 bidimensionally measurable lesion at least 1.5 cm by CT scan
• No primary or secondary CNS lymphoma
• No HIV-related lymphoma
• No known brain metastases
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• ECOG 0-2 OR
• Karnofsky 60-100%
• Life expectancy
• More than 3 months
• Hematopoietic
• Hemoglobin at least 9 g/dL
• Absolute neutrophil count at least 1,000/mm\^3
• * No colony-stimulating factors within 4 weeks before obtaining this result
• Platelet count at least 50,000/mm\^3
• * No platelet transfusion within 4 weeks before obtaining this result
• Hepatic
• Bilirubin no greater than 2 times upper limit of normal (ULN)
• AST and ALT no greater than 2.5 times ULN
• No active hepatitis B or C viral infection
• Renal
• Creatinine no greater than 2 times ULN OR
• Creatinine clearance at least 60 mL/min
• Cardiovascular
• No myocardial infarction within the past 6 months
• No evidence of acute ischemia or new conduction system abnormalities on EKG
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Sodium greater than 130 mEq/L
• HIV negative
• No ongoing or active infection
• No other concurrent uncontrolled illness that would preclude study participation
• No psychiatric illness or social situation that would preclude study compliance
• No prior allergic reaction attributable to compounds of similar chemical or biological composition to bortezomib
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Disease Characteristics
• See Chemotherapy
• At least 4 weeks since prior immunotherapy
• Chemotherapy
• See Disease Characteristics
• More than 4 weeks since prior chemotherapy
• More than 12 weeks since prior high-dose chemotherapy with hematopoietic stem cell support
• Endocrine therapy
• Not specified
• Radiotherapy
• More than 4 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery
• More than 4 weeks since prior major surgery unless fully recovered
• Other
• Recovered from prior therapy
• No other concurrent investigational agents
• No other concurrent investigational or commercial agents or therapies to treat the malignancy